Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6569428

Title:Pharmaceutical products comprising endothelial cell precursors
Inventors:Isner, Jeffrey M.; Weston, MA, USA
Asahara, Takayuki; Arlington, MA, USA
Summary:This invention introduces novel methods of using endothelial progenitor cells. Described herein is a pharmaceutical product comprising a nucleic acid encoding an endothelial cell mitogen and endothelial cell (EC) progenitors, in a physiologically acceptable administrable form, wherein the EC progenitors are CD34+, Flk-1+, and tie-2+. Therapeutic applications are provided in the regulation of angiogenesis and in the treatment of tumors of ischemia, as well as in the treatment of injured blood vessels and in the detection of ischemic tissue or injured vessels in vivo. Further disclosed are pharmaceutical products comprising EC progenitors for use in the regulation of angiogenesis, whether in the enhancement or inhibition of blood vessel formation. Various embodiments of the invention include EC progenitors which can be used to enhance angiogenesis or to deliver an angiogenesis modulator to sites of angiogenesis, whether pathologic or utilitarian. Also provided are therapeutic uses of EC progenitors in inducing re-endothelialization of an injured blood vessel, and thus in reducing restenosis by indirectly inhibiting smooth muscle cell proliferation.
Abstract:
US Patent Website:Click Here for Full Text of Patent
Title Number:US6569428
Application Number:US1999000228020
Date Filed:11/01/1999
Date Published:27/05/2003
Assignee:St. Elizabeth's Medical Center of Boston, Inc., Boston, MA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  8/12/2020